Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have prostate cancer that has spread to other parts of the body, is getting worse, and is no longer responding to hormone therapy.
- Your tumors show high levels of a protein called PSMA, confirmed by a special type of scan called a 68Ga-PSMA PET/CT scan.
Who may not be able to join:
- Your blood shows that your kidneys are not working well enough (a specific kidney marker called creatinine is too high in your blood).
- Your blood shows that you are significantly anaemic (your red blood cell level, called haemoglobin, is too low).
- Your blood shows that your white blood cell count is too low, which can affect your ability to fight infection.
- Your blood shows that your platelet count is too low, which can affect how well your blood clots.
- Your blood shows that your liver is not working well enough (a substance called bilirubin is too high).
- Your blood shows that your albumin level (a protein that helps carry nutrients in your blood) is above a certain level (confirm with trial site, as this may be a minimum rather than maximum threshold).
- You have been diagnosed with heart failure or a serious heart condition that means your heart is not pumping well enough.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhaohui Zhu Zhu, MD, Peking Union Medical College Hospital
Phone: 86-13611093752
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dosimetry of normal organs and tumors; Hematologic adverse events collection; Hepatic and renal toxic events collection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.